TransMedics Group, Inc. $TMDX Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. lessened its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 4.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 111,640 shares of the company’s stock after selling 5,730 shares during the period. Oppenheimer & Co. Inc.’s holdings in TransMedics Group were worth $12,526,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Royal Bank of Canada boosted its position in TransMedics Group by 47.9% during the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after purchasing an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of TransMedics Group by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after purchasing an additional 868 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares during the period. KLP Kapitalforvaltning AS boosted its position in shares of TransMedics Group by 3.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,600 shares of the company’s stock worth $884,000 after buying an additional 200 shares during the period. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of TransMedics Group in the second quarter valued at about $286,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $136.34 on Tuesday. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. TransMedics Group, Inc. has a 1 year low of $62.07 and a 1 year high of $156.00. The firm’s 50-day simple moving average is $132.84 and its 200-day simple moving average is $124.80. The firm has a market cap of $4.66 billion, a PE ratio of 55.20 and a beta of 2.06.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the transaction, the insider owned 13,955 shares of the company’s stock, valued at $2,026,545.10. This trade represents a 17.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 8,920 shares of company stock worth $1,257,310 over the last quarter. 7.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Morgan Stanley boosted their price target on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Needham & Company LLC lifted their price target on shares of TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Finally, Jefferies Financial Group initiated coverage on shares of TransMedics Group in a report on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and an average target price of $144.25.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.